Skip to content

Chlorhexidine Vaginal and Infant Wash in Pakistan

Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00121394
Enrollment
5008
Registered
2005-07-21
Start date
2005-06-30
Completion date
2008-06-30
Last updated
2014-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Sepsis

Keywords

Chlorhexidine, Vaginal wash, Neonatal mortality, Sepsis, Global Network, Maternal and child health, Women's Health, International, Pakistan

Brief summary

Infection is a major health problem during birth in Pakistan. This study will look at the possibility of using a septic wash to help improve health during birth in Karachi, Pakistan.

Detailed description

Sepsis in mother and infant is a major cause of perinatal morbidity and mortality in low-resource settings. Several studies have investigated the likelihood that an anti-bacterial agent, chlorhexidine, administered during labor and delivery to mother and infant could reduce the risk of infection and of subsequent maternal and infant morbidity and mortality. In this trial, chlorhexidine wash and placebo will be randomly administered to women in labor and newborn infants in a public hospital in Karachi, Pakistan. Delivery attendants will administer 0.6% chlorhexidine solution every four hours until delivery (4 washes maximum) and one neonatal wash with the same solution. The control group will receive 200 ml of sterile physiologic saline solution. A total of 5000 women will be randomized in the hospital study, 2500 control and 2500 intervention. All women and infants will be evaluated 24 hours post delivery and at a 7-day follow-up. Women who delivered at home will also receive a 28 days post-partum assessment. Women will be carefully monitored for side effects to the dosage. In addition a community-based feasibility trial of 200 patients (100 CHX, 100 control) will be completed.

Interventions

PROCEDUREChlorhexidine vaginal and infant wash

Sponsors

Global Network for Women's and Children's Health Research
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
RTI International
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
Aga Khan University
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
NICHD Global Network for Women's and Children's Health
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Gravidas with living fetus delivering at home in the care of identified study birth attendant (community) or admitted to the identified hospital (Civil Hospital Karachi) for delivery

Exclusion criteria

* Contraindications to cervical exam (e.g., placenta previa) * Active genital herpes or vulvovaginal ulceration * Known or suspected allergy to chlorhexidine * Fetus with face presentation * Fetal death * Unwilling/unable to give informed consent * Less than 16 years of age

Design outcomes

Primary

MeasureTime frame
Neonatal death or severe sepsis7 days

Secondary

MeasureTime frame
Maternal: clinical chorioamnionitis, clinical endometritis, urinary tract infection, sepsis, length of hospitalization, readmission to hospital, death7 days
Neonatal: receipt of antibiotics, duration of hospitalization, readmission to hospital7 dats

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026